Subcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): Randomized, open-label, phase 3 AQUILA study.

被引：0

作者：

Dimopoulos, Meletios A.

Voorhees, Peter M.

Goldschmidt, Hartmut

Baker, Ross I.

Shi, Yingqi

Rousseau, Els

Dennis, Robyn Monet

Carson, Robin L.

Rajkumar, S. Vincent

机构：

[1] Natl & Kapodistrian Univ Athens, Athens, Greece

[2] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[3] Univ Heidelberg Hosp, Internal Med 5, Heidelberg, Germany

[4] Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[5] Murdoch Univ, Perth Blood Inst, Perth, Australia

[6] Janssen Res & Dev LLC, Spring House, PA USA

[7] Mayo Clin, Div Hematol, Rochester, MN USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS8075

引用

页数：1

共 50 条

[21] Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)
Usmani, Saad Z.
Nahi, Hareth
Mateos, Maria-Victoria
Lokhorst, Henk M.
Chari, Ajai
Kaufman, Jonathan L.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Benboubker, Lotfi
Hellemans, Peter
Masterson, Tara
Clemens, Pamela L.
Ahmadi, Tahamtan
Liu, Kevin
San-Miguel, Jesus
BLOOD, 2016, 128 (22)
[22] Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study
Chari, Ajai
Nahi, Hareth
Mateos, Maria-Victoria
Lokhorst, Henk M.
Kaufman, Jonathan L.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Benboubker, Lotfi
Hellemans, Peter
Masterson, Tara
Clemens, Pamela L.
Liu, Kevin
San-Miguel, Jesus F.
Usmani, Saad Z.
BLOOD, 2017, 130
[23] Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
Mateos, Maria-Victoria
Nahi, Hareth
Legiec, Wojciech
Grosicki, Sebastian
Vorobyev, Vladimir
Spicka, Ivan
Hungria, Vania
Korenkova, Sibirina
Bahlis, Nizar
Flogegard, Max
Blade, Joan
Moreau, Philippe
Kaiser, Martin
Iida, Shinsuke
Laubach, Jacob
Magen, Hila
Cavo, Michele
Hulin, Cyrille
White, Darrell
De Stefano, Valerio
Clemens, Pamela L.
Masterson, Tara
Lantz, Kristen
O'Rourke, Lisa
Heuck, Christoph
Qin, Xiang
Parasrampuria, Dolly A.
Yuan, Zhilong
Xu, Steven
Qi, Ming
Usmani, Saad Z.
LANCET HAEMATOLOGY, 2020, 7 (05): : E370 - E380
[24] Subcutaneous daratumumab in Chinese patients with relapsed or refractory multiple myeloma: an open-label, multicenter, phase 1 study (MMY1010)
An, Gang
Ge, Zheng
Jing, Hongmei
Liu, Jing
Yang, Guoping
Feng, Ru
Xu, Zhongyuan
Qi, Ming
Wang, Jianping
Song, Juanjuan
Zhou, Wei
Sun, Binbin
Zhu, Dian
Chen, Xi
Cui, Canchan
Qiu, Lugui
BLOOD SCIENCE, 2024, 6 (03): : e00193
[25] Phase 3, open-label, non-inferiority study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma: body weight subgroup analysis of Columba
Kaiser, M.
Mateos, M. -V.
Usmani, S. Z.
Grosicki, S.
Vorobyev, V.
Spicka, I.
Hungria, V.
Korenkova, S.
Bahlis, N.
Flogegard, M.
Blade, J.
Moreau, P.
Iida, S.
Laubach, J.
Masterson, T.
Lantz, K.
O'Rourke, L.
Qin, X.
Parasrampuria, D. A.
Heuck, C.
Qi, M.
Nahi, H.
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 22 - 22
[26] A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma
Patel, Roshani
Bhaskarla, Amrit
Gordon, Max J.
Emanuel, Michael
Colon, Dana I. Delgado
Wang, Hao-Wei
Yuan, Constance M.
Lindenberg, Liza
Mena, Esther
Turkbey, Baris
Micheletti, Nick
Yee, Laura M.
Patel, Nisha
Maric, Irina
Braylan, Raul C.
Calvo, Katherine R.
Staudt, Louis M.
Young, Ryan M.
Roschewski, Mark
Kazandjian, Dickran
Hill, Elizabeth
BLOOD, 2024, 144 : 7059 - 7060
[27] LIGHTHOUSE (OP-108): A phase 3 study of melflufen in combination with dexamethasone (dex) and daratumumab (dara) versus dara in relapsed/refractory multiple myeloma (RRMM) patients (pts).
Mateos, Maria-Victoria
Pour, Ludek
Ocio, Enrique M.
Sonneveld, Pieter
Blixt, Catarina Jansson
Larsson, Kajsa
Palmer, Linda
Richardson, Paul G.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[28] A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety
Nadeem, Omar
Redd, Robert
Stampleman, Laura V.
Matous, Jeffrey V.
Yee, Andrew J.
Zonder, Jeffrey A.
Kin, Andrew
Rosenblatt, Jacalyn
Bustoros, Mark
Prescott, Julia
Savell, Alexandra
Guimond, Kathleen
Frey, Erin
Styles, Rachel
Bielawski, Adrienne
Boehner, Cody J.
Kham, Nang
Sperling, Adam S.
Bianchi, Giada
Laubach, Jacob P.
Castillo, Jorge J.
Munshi, Nikhil C.
Anderson, Kenneth C.
Richardson, Paul G.
Trippa, Lorenzo
Ghobrial, Irene M.
BLOOD, 2019, 134
[29] Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study
Chari, Ajai
Rodriguez-Otero, Paula
McCarthy, Helen
Suzuki, Kenshi
Hungria, Vania
Balari, Anna Sureda
Perrot, Aurore
Hulin, Cyrille
Magen, Hila
Iida, Shinsuke
Maisnar, Vladimir
Karlin, Lionel
Pour, Ludek
Parasrampuria, Dolly A.
Masterson, Tara
Kosh, Michele
Yang, Shiyi
Delioukina, Maria
Qi, Ming
Carson, Robin
Touzeau, Cyrille
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 192 (05) : 869 - 878
[30] Randomized, open-label, phase 2/3 study of daratumumab (DARA) with or without JNJ-63723283, an anti-PD-1 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM).
Van Droogenbroeck, Jan
Vlummens, Philip
Lavi, Noa
Wu, Ka Lung
Fu, Jiayu
Feng, Huaibao
Carson, Robin L.
Crist, Wendy
Schecter, Jordan
Cohen, Yael
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →